What is it about?
Portal vein thrombosis (PVT) is a common complication after transarterial chemoembolization (TACE) in hepatocellular carcinoma (HCC). This is the first clinical study to evaluate the role of low-molecular-weight heparins (LMWHs) with TACE in HCC for the prevention of thromboembolism complications (PVT).
Featured Image
Why is it important?
Portal vein thrombosis (PVT) is a common complication after transarterial chemoembolization (TACE) in hepatocellular carcinoma (HCC). This is the first clinical study to evaluate the role of low-molecular-weight heparins (LMWHs) with TACE in HCC for the prevention of thromboembolism complications (PVT).
Perspectives
MWH with TACE in HCC is strongly recommended for prevention of thromboembolism complications (PVT). However, larger randomized-controlled studies are needed to confirm these obvious findings
sherief Abd-Elsalam
Tanta University
Read the Original
This page is a summary of: Role of low-molecular-weight heparins in prevention of thromboembolic complication after transarterial chemoembolization in hepatocellular carcinoma, European Journal of Gastroenterology & Hepatology, March 2017, Wolters Kluwer Health,
DOI: 10.1097/meg.0000000000000790.
You can read the full text:
Resources
Contributors
The following have contributed to this page
